|

MindMed’s CEO RESIGNS! What’s NEXT for MMED / MNMD Stock? [ My Thoughts? ]

ByPsychedelic Spotlight

MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
(MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.

In this episode, we’ll cover several things.

1.What happened?
2.My general thoughts on the leadership change.
3.My thoughts on JR Rahn’s successes and his departure.
4.What Robert Barrow brings to the table as CEO.

Links:
MindMed changes leadership:
https://mindmed.co/news/press-release/mindmed-announces-chief-executive-officer-transition/

Robert Barrow background:
https://mindmed.co/team/robert-barrow-1/
https://www.newswire.ca/news-releases/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience-862550304.html

General Reddit sentiment about MindMed’s leadership change:

Expected this sub to be on fire this morning but so glad you all are cheering JR and feeling good about the next phase.
byu/ShepherdingLight inMindMedInvestorsClub

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindmedNews

Similar Posts

  • Interview With Steven Huang, DEI Consultant at MAPS and Numinus

    Listen, Podcasts

    Steven’s consultancy company, Millennial HR Design, focuses on the intersection of DEI and psychedelics, where he intends to be a leverage point for the psychedelics industry to better understand their impact on marginalized communities. With nearly 10 years of industry experience, Steven hopes for more diverse and equitable representation in the psychedelic space. 

  • MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]

    Listen, Videos

    MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
    Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.

    Also, there were 0 cases of serious adverse side effects in the MDMA group.

    So which companies will be the largest benefactors of these results?

    Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently

    2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.

    3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.

    4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.

    5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.

    Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
    Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
    Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
    Link to Numinus (NUMI): https://numinus.ca/
    Link to Atai Life Sceinces : https://www.atai.life/
    Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    Clinical trials :

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #NUMIStock

  • Interview With Nick Levich

    Listen, Podcasts

    Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.

  • Interview With Laura Dawn

    Listen, Podcasts

    In today’s episode of the Psychedelic Spotlight podcast, we feature Laura Dawn- a microdosing mentor, visionary life coach, business consultant, author, international speaker, and host of the Psychedelic Leadership podcast.